Maureen T Kelly Selected Research

fenofibric acid

6/2014	Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
8/2013	A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
11/2012	Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
4/2012	One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
9/2011	Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). [email protected].
5/2011	Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.
3/2011	Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
2/2011	Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
2/2011	Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
10/2010	Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maureen T Kelly Research Topics

Disease

19	Dyslipidemias (Dyslipidemia) 06/2014 - 12/2008
3	Coronary Disease (Coronary Heart Disease) 06/2014 - 01/2008
2	Type 2 Diabetes Mellitus (MODY) 02/2011 - 01/2010
2	Hypertriglyceridemia 02/2011 - 01/2010
1	Coronary Artery Disease (Coronary Atherosclerosis) 06/2014
1	Chronic Renal Insufficiency 08/2013
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2012
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2010
1	Hypercholesterolemia 01/2010
1	Rhabdomyolysis 01/2010
1	Myotoxicity 01/2010
1	Headache (Headaches) 12/2008
1	Nasopharyngitis 12/2008
1	Respiratory Tract Infections (Respiratory Tract Infection) 12/2008
1	Back Pain (Backache) 12/2008

Drug/Important Bio-Agent (IBA)

20	fenofibric acid FDA Link 06/2014 - 12/2008
17	LipidsIBA 08/2013 - 01/2008
12	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 06/2014 - 12/2008
10	Rosuvastatin Calcium (Crestor)FDA Link 08/2013 - 01/2009
9	Triglycerides (Triacylglycerol)IBA 06/2014 - 01/2009
9	LDL CholesterolIBA 06/2014 - 01/2009
8	HDL CholesterolIBA 06/2014 - 01/2009
8	oxidized low density lipoproteinIBA 11/2012 - 01/2009
4	Atorvastatin (Lipitor)FDA Link 06/2014 - 02/2009
4	2- (4- (4- chlorobenzoyl)phenoxy)- 2- methylpropanoic acidIBA 05/2009 - 01/2009
3	Fibric Acids (Fibrates)IBA 06/2014 - 01/2010
3	Simvastatin (Zocor)FDA LinkGeneric 02/2011 - 01/2009
2	Choline (Choline Chloride)IBA 06/2014 - 01/2009
2	Lipoproteins (Lipoprotein)IBA 11/2012 - 05/2011
2	Biomarkers (Surrogate Marker)IBA 09/2011 - 05/2011
2	Apolipoproteins B (ApoB)IBA 05/2011 - 02/2011
2	LDL Lipoproteins (beta Lipoproteins)IBA 03/2011 - 02/2009
2	HDL LipoproteinsIBA 03/2011 - 02/2009
2	ApolipoproteinsIBA 02/2011 - 01/2010
1	Fenofibrate (CiL)FDA LinkGeneric 06/2014
1	C-Reactive ProteinIBA 09/2011
1	Ezetimibe (Zetia)FDA Link 10/2010
1	SaltsIBA 01/2009

Therapy/Procedure

17	Therapeutics 06/2014 - 12/2008
1	Aftercare (After-Treatment) 02/2011